Rubraca® (rucaparib) – Voluntary indication withdrawal

- On June 10, 2022, the FDA approved a voluntary indication withdrawal for Clovis Oncology's Rubraca (rucaparib), for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.

- This decision does not affect the other approved indications for Rubraca, which include:

  — Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy; and
  — Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for Rubraca.